The US FDA Approves Lupin’s Armlupeg (Biosimilar, Neulasta)

Shots: The US FDA has approved Armlupeg (pegfilgrastim-unne) as a biosimilar version of Neulasta (pegfilgrastim) Armlupeg (6 mg/0.6 mL) is administered as a single-dose SC injection. It is indicated to reduce the incidence of febrile neutropenia in pts with non-myeloid cancers undergoing myelosuppressive CT and to improve survival following acute myelosuppressive radiation exposure Armlupeg will be produced at Lupin’s Biotech facility…

ByDipanshu DixitDecember 1, 2025

NEWS

Abbott Expands Leadership in Cancer Diagnostics with ~$23B Acquisition of Exact Sciences

Shots: Abbott has entered into a definitive agreement to acquire Exact Sciences, making Exact a subsidiary of Abbott upon deal completion As per the deal, Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of ~$21B & an estimated enterprise value of $23B, with financing that includes absorbing Exact’s ~$1.8B in…

ByRidhi RastogiNovember 21, 2025

NEWS

GSK Collaborates with LTZ Therapeutics to Advance Myeloid Cell Engager Therapies in Oncology

Shots: GSK has entered into a strategic research collaboration with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) in oncology, leveraging LTZ’s immune-engager platform Under the collaboration, GSK & LTZ aim to develop up to four MCE therapies for hematologic cancers & solid tumors, with GSK receiving an exclusive option to…

ByRidhi RastogiNovember 19, 2025

NEWS

J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Shots: J&J has entered into a definitive agreement to acquire Halda Therapeutics, strengthening its oncology pipeline As per the deal, J&J will acquire Halda for $3.05B in cash, with the deal treated as a business combination & expected to close in the coming months Acquisition will add Halda’s Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform…

ByRidhi RastogiNovember 18, 2025

NEWS

Adagene Enters ~$845M Licensing Deal with Third Arc Bio to Develop Masked CD3 T Cell Engagers

Shots: Third Arc Bio has entered into a licensing agreement with Adagene to utilize its SAFEbody technology platform for generating masked CD3 T cell engagers against unique tumor-associated antigens As per the deal, Third Arc Bio will gain global rights to research, develop & commercialize 2 candidate molecules, while Adagene will receive a no-cost option…

ByRidhi RastogiNovember 14, 2025

MAGAZINE

PharmaShots Magazine-November-2025 Edition

Radiopharmaceuticals, once viewed as a niche scientific endeavor, are now revolutionizing the way we detect and treat cancer. By fusing the targeting precision of molecular medicine with the therapeutic strength of radiation, these compounds are unlocking new possibilities in oncology, bringing renewed hope to patients where conventional therapies often fall short From early detection to…

ByAditya SinghNovember 13, 2025

NEWS

Geneseeq’s PanTRKare NTRK Gene Fusion Detection Kit Receives NMPA Approval as Companion Diagnostic

Shots: The Chinese NMPA has approved PanTRKare NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for Roche’s Rozlytrek (entrectinib) The kit was validated through a large-scale study across 33 tumor types & 2,400+ clinical samples, where it demonstrated high accuracy, sensitivity, & reproducibility, with detection of 200+ unique NTRK fusion variants Also, clinical bridging studies…

ByRidhi RastogiNovember 11, 2025

NEWS

Daiichi Sankyo Reports First Patient Dosing in P-I Trial of DS3610 for Solid Tumors

Shots: Daiichi Sankyo has dosed the first patient with DS3610 in P-I trial for the treatment of advanced, metastatic or unresectable solid tumors The P-I trial will evaluate DS-3610 in advanced or metastatic solid tumors to determine the recommended dose, assessing PK & immunogenicity endpoints plus safety endpoints incl. DLTs & AEs. Exploratory endpoints like…

ByRidhi RastogiNovember 11, 2025

INSIGHTS+

Know Your Investor: Samsara Biocapital (November’25 Edition)

Shots: Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such…

ByPrince GiriNovember 5, 2025

NEWS

HUTCHMED Completes Enrollment in Global P-III (SAFFRON) Study of Orpathys + Tagrisso in Lung Cancer Patients

Shots: HUTCHMED completed the pts enrollment in the global P-III (SAFFRON) study evaluating Orpathys (savolitinib) + Tagrisso (osimertinib) vs Pt. based doublet CT in pts with EGFR-mutated, MET-overexpressed, and/or amplified, LA/M NSCLC after progression on Tagrisso, with the last patient being randomized on 31 Oct’25 The Ongoing P-III (SAFFRON) study is evaluating the efficacy and…

ByPrince GiriNovember 5, 2025

The US FDA Approves Lupin’s Armlupeg (Biosimilar, Neulasta)

Abbott Expands Leadership in Cancer Diagnostics with ~$23B Acquisition of Exact Sciences

GSK Collaborates with LTZ Therapeutics to Advance Myeloid Cell Engager Therapies in Oncology

J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Adagene Enters ~$845M Licensing Deal with Third Arc Bio to Develop Masked CD3 T Cell Engagers

PharmaShots Magazine-November-2025 Edition

Geneseeq’s PanTRKare NTRK Gene Fusion Detection Kit Receives NMPA Approval as Companion Diagnostic

Daiichi Sankyo Reports First Patient Dosing in P-I Trial of DS3610 for Solid Tumors

Know Your Investor: Samsara Biocapital (November’25 Edition)

HUTCHMED Completes Enrollment in Global P-III (SAFFRON) Study of Orpathys + Tagrisso in Lung Cancer Patients

Contact US

FOLLOW US